Standard BioTools Inc (LAB) is now in the Overvalued zone, suggesting that its current forward PS ratio of 6.28 is considered Overvalued compared with the five-year average of -9.61. The fair price of Standard BioTools Inc (LAB) is between 0.28 to 0.75 according to relative valuation method. Compared to the current price of 1.10 USD , Standard BioTools Inc By Overvalued By 46.48%.

Relative Value

Fair Zone

0.28-0.75

Current Price：1.10

46.48%

Overvalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Standard BioTools Inc (LAB) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Standard BioTools Inc (LAB) has a current Price-to-Book (P/B) ratio of 1.22. Compared to its 3-year average P/B ratio of 0.19, the current P/B ratio is approximately 531.15% higher. Relative to its 5-year average P/B ratio of 1.03, the current P/B ratio is about 17.80% higher. Standard BioTools Inc (LAB) has a Forward Free Cash Flow (FCF) yield of approximately -20.15%. Compared to its 3-year average FCF yield of -26.56%, the current FCF yield is approximately -24.14% lower. Relative to its 5-year average FCF yield of -29.99%, the current FCF yield is about -32.80% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for LAB competitors is 2.78, providing a benchmark for relative valuation. Standard BioTools Inc Corp (LAB.O) exhibits a P/S ratio of 6.28, which is 126.21% above the industry average. Given its robust revenue growth of -49.07%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of LAB increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of LAB in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is LAB currently overvalued or undervalued?

What is Standard BioTools Inc (LAB) fair value?

LAB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Standard BioTools Inc (LAB) is between 0.28 to 0.75 according to relative valuation method.

How does LAB's valuation metrics compare to the industry average?

The average P/S ratio for LAB's competitors is 2.78, providing a benchmark for relative valuation. Standard BioTools Inc Corp (LAB) exhibits a P/S ratio of 6.28, which is 126.21% above the industry average. Given its robust revenue growth of -49.07%, this premium appears unsustainable.

What is the current P/B ratio for Standard BioTools Inc (LAB) as of Mar 03 2026?

As of Mar 03 2026, Standard BioTools Inc (LAB) has a P/B ratio of 1.22. This indicates that the market values LAB at 1.22 times its book value.

What is the current FCF Yield for Standard BioTools Inc (LAB) as of Mar 03 2026?

As of Mar 03 2026, Standard BioTools Inc (LAB) has a FCF Yield of -20.15%. This means that for every dollar of Standard BioTools Inc's market capitalization, the company generates -20.15 cents in free cash flow.

What is the current Forward P/E ratio for Standard BioTools Inc (LAB) as of Mar 03 2026?

As of Mar 03 2026, Standard BioTools Inc (LAB) has a Forward P/E ratio of -23.09. This means the market is willing to pay $-23.09 for every dollar of Standard BioTools Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Standard BioTools Inc (LAB) as of Mar 03 2026?

As of Mar 03 2026, Standard BioTools Inc (LAB) has a Forward P/S ratio of 6.28. This means the market is valuing LAB at $6.28 for every dollar of expected revenue over the next 12 months.

LAB Valuation